Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Conference Call April 30, 2024 8:30 AM ET

Company Participants

Sujal Patel - Co-Founder & Chief Executive Officer
Parag Mallick - Co-Founder & Chief Scientist
Anna Mowry - Chief Financial Officer

Conference Call Participants

Operator

Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Q1 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Jeon E [ph]. Investor Relations. Please go ahead.

Unidentified Company Representative

Thank you. Earlier today, Nautilus released financial results for the quarter ended March 31, 2024. If you haven't received this news release or if you'd like to be added to the Company's distribution list, please send an e-mail to investorrelations@nautilus.bio. Joining me today from Nautilus are Sujal Patel, Co-Founder and CEO; Parag Mallick, Co-Founder and Chief Scientist; and Anna Mowry, Chief Financial Officer.

Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated.

Additional information regarding these risks and uncertainties appears in the section entitled forward-looking in the press release Nautilus issued today, except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast April 30, 2024.

With that, I'll turn the call over to Sujal.

Sujal Patel

Thanks Jeon, and welcome to everyone joining our Q1 2024 earnings call. Q1 was a highly productive quarter for Nautilus as we continue to execute on our vision to establish a new gold standard for the creation and comprehensive analysis of high-value proteomic data.

In order to deliver a range of long discussed and long desired improvements in human health, biomedical research needs a dramatic acceleration in target identification and therapeutic develop. But as they have for many years, researchers remain impeded by the lack of sensitivity, scale and reproducibility of traditional protein analysis method and have emerging affinity based and peptide sequencing matters.